NBTX R3 is a first-in-class radioenhancer. And the background for this particular study is that in melanoma, melanoma has a reputation of being a tumor that is resistant to radiation. So using a radioenhancer with radiation is appealing. And also finding effective treatments for melanoma patients who have progressed on immunotherapy is a great challenge. And so we were also seeing if the combination of the radioenhancer and radiation could elicit anti-tumor immunity and resensitize patients to anti-PD-1 therapy...
NBTX R3 is a first-in-class radioenhancer. And the background for this particular study is that in melanoma, melanoma has a reputation of being a tumor that is resistant to radiation. So using a radioenhancer with radiation is appealing. And also finding effective treatments for melanoma patients who have progressed on immunotherapy is a great challenge. And so we were also seeing if the combination of the radioenhancer and radiation could elicit anti-tumor immunity and resensitize patients to anti-PD-1 therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.